This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Hartmut P. H. Neumann, MD; Charis Eng, MD, PhD; Lois M. Mulligan, PhD; Damjan Glavac, PhD; Ingeborg Zäuner, MD; Bruce A. J. Ponder, PhD, FRCP; Paul A. Crossey, PhD; Eamonn R. Maher, MD; Hiltrud Brauch, PhD

JAMA. 1995;274(14):1149-1151.

Abstract
Objective.
—Multiple endocrine neoplasia, type II (MEN-II) is an autosomal dominant disorder characterized by tumors of thyroid C cells and pheochromocytoma. Recently, germline mutations in the RET proto-oncogene have been identified in patients with MEN-II. The aims of this study were (1) to define the mutations in clinically diagnosed MEN-II families, (2) to compare the results of genetic and biochemical testing, and (3) to evaluate the impact of mutation analyses for the members of these families.

Design.
—Register-based survey study of clinically affected and unaffected members of MEN-II families.

Setting.
—Register of families from Germany and Spain with pheochromocytomas. Two research laboratories at Cambridge University in the United Kingdom.

Patients.
—We investigated consenting affected and unaffected members belonging to a series of 10 families who met the clinical criteria for MEN-II.

Main Outcome Measures.
—(1) Presence or absence of germline mutation in the RETproto-oncogene in affected and unaffected members of the 10 families, and (2) in the absence of RETmutation in a given family, presence or absence of germline mutation in the von Hippel-Lindau (VHL) gene, which is the susceptibility gene involved in a closely related syndrome, von Hippel-Lindau disease.

Results.
—In eight of these families, RETmutations were identified. The specific mutations were detected in all affected members. The remaining two families without RET mutations were subsequently shown to have a mutation within the VHL gene. The VHL mutations were identified in both families and represent a previously undescribed base change. After identification of the mutation, premorbid genetic testing was performed in all MEN-II and VHL families, resulting in detection of asymptomatic carriers in the MEN-II families. Clinically, the two VHL families differed from the eight MEN-II families by the presence of a C-cell tumor in only one individual from each family and extra-adrenal pheochromocytoma in three of nine affected individuals in the two families combined.

Conclusions.
—The diagnosis of MEN-II should be confirmed by molecular genetic analysis and the diagnosis of VHL syndrome should be considered for families with an absence of RET mutations and a preponderance of pheochromocytomas.

(JAMA. 1995;274:1149-1151)

Author Affiliations
From the Department of Nephrology and Hypertension, Albert-Ludwigs-University of Freiburg (Germany) (Drs Neumann and Zäuner); CRC Human Cancer Genetics Research Group, Department of Pathology, Cambridge (United Kingdom) University (Drs Eng, Mulligan, and Ponder); Department of Medicine, DanaFarber Cancer Institute, Harvard Medical School, Boston, Mass (Dr Eng); Departments of Paediatrics and Pathology, Queen's University, Kingston, Ontario (Dr Mulligan); Department of Pathology, Technical University of Munich (Germany) (Drs Glavac and Brauch); National Institute of Chemistry, Ljubljana, Slovenia (Dr Glavac); Molecular Genetics Group, Department of Pathology, Cambridge University (Drs Crossey and Maher); and Department of Clinical Genetics, Addenbrooke's Hospital, Cambridge University (Dr Maher).

Footnotes
Reprint requests to Medizinische Universitätsklinik, Hugstetter Strasse 55, D 79106 Freiburg, Germany (Dr Neumann).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas
Mannelli et al.
J. Clin. Endocrinol. Metab. 2009;94:1541-1547.
ABSTRACT | FULL TEXT  

VHL Mutations Linked to Type 2C von Hippel-Lindau Disease Cause Extensive Structural Perturbations in pVHL
Knauth et al.
J. Biol. Chem. 2009;284:10514-10522.
ABSTRACT | FULL TEXT  

VHL mutation analysis in patients with isolated central nervous system haemangioblastoma
Woodward et al.
Brain 2007;130:836-842.
ABSTRACT | FULL TEXT  

Von Hippel-Lindau disease and endocrine tumour susceptibility.
Woodward and Maher
Endocr Relat Cancer 2006;13:415-425.
ABSTRACT | FULL TEXT  

Genetics of phaeochromocytoma
Maher
Br Med Bull 2006;79-80:141-151.
ABSTRACT | FULL TEXT  

Pheochromocytoma: State-of-the-Art and Future Prospects
Bravo and Tagle
Endocr. Rev. 2003;24:539-553.
ABSTRACT | FULL TEXT  

VHL2C Phenotype in a German von Hippel-Lindau Family with Concurrent VHL Germline Mutations P81S and L188V
Weirich et al.
J. Clin. Endocrinol. Metab. 2002;87:5241-5246.
ABSTRACT | FULL TEXT  

The pressure rises: update on the genetics of phaeochromocytoma
Maher and Eng
Hum Mol Genet 2002;11:2347-2354.
ABSTRACT | FULL TEXT  

Identification of Cyclin D1 and Other Novel Targets for the von Hippel-Lindau Tumor Suppressor Gene by Expression Array Analysis and Investigation of Cyclin D1 Genotype as a Modifier in von Hippel-Lindau Disease
Zatyka et al.
Cancer Res. 2002;62:3803-3811.
ABSTRACT | FULL TEXT  

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
Hoffman et al.
Hum Mol Genet 2001;10:1019-1027.
ABSTRACT | FULL TEXT  

Contrasting effects on HIF-1{{alpha}} regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
Clifford et al.
Hum Mol Genet 2001;10:1029-1038.
ABSTRACT | FULL TEXT  

Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes
Eisenhofer et al.
J. Clin. Endocrinol. Metab. 2001;86:1999-2008.
ABSTRACT | FULL TEXT  

Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma
Pacak et al.
ANN INTERN MED 2001;134:315-329.
ABSTRACT | FULL TEXT  

Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only
Hes et al.
J. Med. Genet. 2000;37:939-943.
ABSTRACT | FULL TEXT  

Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes
Woodward et al.
J. Med. Genet. 2000;37:348-353.
ABSTRACT | FULL TEXT  

Clinical Epidemiological Quality in Molecular Genetic Research: The Need for Methodological Standards
Bogardus et al.
JAMA 1999;281:1919-1926.
ABSTRACT | FULL TEXT  

RET Proto-Oncogene in the Development of Human Cancer
Eng
JCO 1999;17:380-380.
ABSTRACT | FULL TEXT  

Sporadic Pheochromocytomas Are Rarely Associated with Germline Mutations in the vhl Tumor Suppressor Gene or the ret Protooncogene
Brauch et al.
J. Clin. Endocrinol. Metab. 1997;82:4101-4104.
ABSTRACT | FULL TEXT  

The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease
Eng
NEJM 1996;335:943-951.
FULL TEXT  

Von Hippel-Lindau Disease and Pheochromocytoma
Walther and Linehan
JAMA 1996;275:839-840.
ABSTRACT